Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
ChromaDex's Niagen shows social deficit reduction in mouse model of autism » 06:37
07/16/20
07/16
06:37
07/16/20
06:37
CDXC

ChromaDex

$5.20 /

+0.19 (+3.79%)

ChromaDex announced the…

ChromaDex announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen in addressing social deficits in Autism Spectrum Disorder. This new study joins a body of preclinical data demonstrating that boosting NAD+ - nicotinamide adenine dinucleotide - levels may have a positive effect on cognitive health. The study was the first to evaluate Niagen in an Autism model. Daily Niagen supplementation was found to correct social deficits such as fearful and anxiety-like behavior in the male CD157 mice. Following supplementation, these mice were better able to recognize and display interest in other mice. More research is required to translate the health potential of Niagen from mice to humans. Over 40 human clinical trials have been or are being conducted on Niagen across a multitude of organ systems and chronic conditions. ChromaDex has demonstrated the safety and efficacy of Niagen in ten published human trials and over 20 ongoing studies and has achieved government regulatory acceptance in the U.S., Canada, the E.U., and Australia.

ShowHide Related Items >><<
CDXC ChromaDex
$5.20 /

+0.19 (+3.79%)

CDXC ChromaDex
$5.20 /

+0.19 (+3.79%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
CDXC ChromaDex
$5.20 /

+0.19 (+3.79%)

Hot Stocks
ChromaDex's Niagen shows anti-viral effect in new Coronavirus study » 06:40
07/09/20
07/09
06:40
07/09/20
06:40
CDXC

ChromaDex

$4.77 /

+0.25 (+5.53%)

ChromaDex announced the…

ChromaDex announced the latest preclinical findings indicating Niagen inhibits replication of a form of Coronavirus, the virus that causes COVID-19 infection, in mouse cells. The preclinical study results were published July 8 on scientific publishing website bioRxiv.org. The research previously demonstrated in a preclinical cell model that levels of the coenzyme NAD+ were depleted up to 80% in Coronavirus-infected cells. The researchers hypothesized that raising NAD+ levels with nicotinamide riboside, or Niagen, may have an anti-viral effect. These latest results confirmed their hypothesis by demonstrating that cell lines infected with a type of Coronavirus had decreased viral replication when supplemented with NR. Additional research is necessary to explore the role NAD may play in maintaining a proportional inflammatory response to infection, and whether a depletion of NAD may worsen the "cytokine storm" that results in the fatal acute respiratory distress syndrome seen in some COVID patients. Dr. Brenner and the team of scientists are continuing their investigations into the antiviral potential of Niagen in order to translate the findings from the lab to the clinic. Ultimately, clinical trials are required to determine whether Niagen impacts COVID-19 infection in humans.

ShowHide Related Items >><<
CDXC ChromaDex
$4.77 /

+0.25 (+5.53%)

CDXC ChromaDex
$4.77 /

+0.25 (+5.53%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
CDXC ChromaDex
$4.77 /

+0.25 (+5.53%)

Hot Stocks
ChromaDex to begin preclinical study of Niagen with the NIAID » 06:36
07/07/20
07/07
06:36
07/07/20
06:36
CDXC

ChromaDex

$4.50 /

-0.03 (-0.66%)

ChromaDex announced the…

ChromaDex announced the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH. This study will assess if administration of Niagen, or nicotinamide riboside, or NR, can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDex's patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD+ levels. The study is part of the ChromaDex External Research Program, or CERP, in which ChromaDex's NR ingredient and placebos are provided to researchers at no cost. This joint study is designed to assess in mice and hamsters whether NR supplementation prior to infection can reduce progression of the infection either by limiting viral replication or modulating the inflammatory response, having a positive impact on disease severity and duration, as well as increasing survival.

ShowHide Related Items >><<
CDXC ChromaDex
$4.50 /

-0.03 (-0.66%)

CDXC ChromaDex
$4.50 /

-0.03 (-0.66%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
CDXC ChromaDex
$4.50 /

-0.03 (-0.66%)

Over a month ago
Hot Stocks
ChromaDex announces results of new clinical studies of Niagen » 06:35
06/30/20
06/30
06:35
06/30/20
06:35
CDXC

ChromaDex

$4.54 /

+0.19 (+4.37%)

ChromaDex announced the…

ChromaDex announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen, or nicotinamide riboside or NR, in bolstering cellular health to counteract or reduce progression of numerous degenerative conditions. The proven ability of Niagen to raise NAD+ levels was found to contribute to positive effects in preclinical models of aging, fertility, and circadian rhythms, and in a clinical study on liver function. Several of these studies were made possible through the global ChromaDex External Research Program, or CERP, which offers the patented Niagen ingredient to research institutions and universities at no cost. The latest research from CERP includes a recent publication in Biochemical Pharmacology, which found that nicotinamide riboside was unique in its ability in vitro to reduce inflammation in endothelial cells from mice. This study builds on existing clinical and preclinical NR research in the area of cardiovascular health. Another small human pilot study supported by CERP revealed that NR, in combination with other clinically validated nutrients, improved biomarkers of liver function in healthy subjects. These markers, the investigators surmised, may be important in non-alcoholic fatty liver disease. In a third CERP study, NR was found to restore a "younger" circadian rhythm to older mice. Following NR supplementation, older mice re-established cellular function reflective of younger mice, and even displayed a "physically active period" that they had lost with age.

ShowHide Related Items >><<
CDXC ChromaDex
$4.54 /

+0.19 (+4.37%)

CDXC ChromaDex
$4.54 /

+0.19 (+4.37%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
CDXC ChromaDex
$4.54 /

+0.19 (+4.37%)

Conference/Events
Lytham Partners to hold a virtual conference » 04:55
06/25/20
06/25
04:55
06/25/20
04:55
MOGO

Mogo

$0.95 /

-0.0403 (-4.05%)

, SANW

S&W Seed

$2.21 /

-0.04 (-1.78%)

, MNKD

MannKind

$1.86 /

-0.265 (-12.47%)

, CDXC

ChromaDex

$4.46 /

-0.11 (-2.41%)

, SNWV

Sanuwave Health

$0.00 /

+ (+0.00%)

, EAST

Eastside Distilling

$1.52 /

+0.03 (+2.01%)

, AZZ

AZZ Inc.

$32.75 /

-1.44 (-4.21%)

, ICCC

Immucell

$4.43 /

-0.105 (-2.32%)

, INFU

InfuSystem

$11.81 /

-0.5 (-4.06%)

, LIQT

LiqTech

$5.41 /

-0.17 (-3.05%)

, TNP

TEN, Ltd.

$2.02 /

-0.1 (-4.72%)

Investor Growth Virtual…

Investor Growth Virtual Conference will be held on June 24-25 at 9 am. Webcast Link

ShowHide Related Items >><<
TNP TEN, Ltd.
$2.02 /

-0.1 (-4.72%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.21 /

-0.04 (-1.78%)

MOGO Mogo
$0.95 /

-0.0403 (-4.05%)

MNKD MannKind
$1.86 /

-0.265 (-12.47%)

LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

INFU InfuSystem
$11.81 /

-0.5 (-4.06%)

ICCC Immucell
$4.43 /

-0.105 (-2.32%)

EAST Eastside Distilling
$1.52 /

+0.03 (+2.01%)

CDXC ChromaDex
$4.46 /

-0.11 (-2.41%)

AZZ AZZ Inc.
$32.75 /

-1.44 (-4.21%)

MOGO Mogo
$0.95 /

-0.0403 (-4.05%)

06/04/20 B. Riley FBR
Mogo price target lowered to $3 from $4 at B. Riley FBR
03/30/20 B. Riley FBR
Mogo Finance price target lowered to $4 from $7 at B. Riley FBR
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
SANW S&W Seed
$2.21 /

-0.04 (-1.78%)

MNKD MannKind
$1.86 /

-0.265 (-12.47%)

12/24/19
Fly Intel: Top five analyst actions
12/24/19 Oppenheimer
MannKind initiated with an Outperform at Oppenheimer
10/25/19
Fly Intel: Top five analyst initiations
10/24/19 Cantor Fitzgerald
Cantor Fitzgerald starts MannKind at Overweight as Afrezza uptake gains traction
CDXC ChromaDex
$4.46 /

-0.11 (-2.41%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

EAST Eastside Distilling
$1.52 /

+0.03 (+2.01%)

AZZ AZZ Inc.
$32.75 /

-1.44 (-4.21%)

ICCC Immucell
$4.43 /

-0.105 (-2.32%)

INFU InfuSystem
$11.81 /

-0.5 (-4.06%)

06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

01/22/20 Lake Street
LiqTech analyst increases confidence in recovery, says Lake Street
12/17/19 Lake Street
LiqTech to recover from furnace throughput challenges, says Lake Street
11/14/19 Craig-Hallum
LiqTech post-earnings pullback a buying opportunity, says Craig-Hallum
09/06/19 Stephens
LiqTech can materially ramp revenue and profits in 2020, says Stephens
TNP TEN, Ltd.
$2.02 /

-0.1 (-4.72%)

06/18/20
Fly Intel: Top five analyst downgrades
06/18/20 Stifel
TEN, Ltd. downgraded to Hold from Buy at Stifel
TNP TEN, Ltd.
$2.02 /

-0.1 (-4.72%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.21 /

-0.04 (-1.78%)

MNKD MannKind
$1.86 /

-0.265 (-12.47%)

LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

EAST Eastside Distilling
$1.52 /

+0.03 (+2.01%)

CDXC ChromaDex
$4.46 /

-0.11 (-2.41%)

AZZ AZZ Inc.
$32.75 /

-1.44 (-4.21%)

LIQT LiqTech
$5.41 /

-0.17 (-3.05%)

Conference/Events
Lytham Partners to hold a virtual conference » 08:46
06/24/20
06/24
08:46
06/24/20
08:46
MOGO

Mogo

$0.99 /

+0.0046 (+0.46%)

, SANW

S&W Seed

$2.25 /

+ (+0.00%)

, MNKD

MannKind

$2.13 /

-0.08 (-3.63%)

, CDXC

ChromaDex

$4.57 /

-0.02 (-0.44%)

, SNWV

Sanuwave Health

$0.00 /

+ (+0.00%)

, EAST

Eastside Distilling

$1.49 /

+0.04 (+2.76%)

, AZZ

AZZ Inc.

$34.19 /

+0.52 (+1.54%)

, ICCC

Immucell

$4.53 /

+0.03 (+0.67%)

, INFU

InfuSystem

$12.31 /

+0.56 (+4.77%)

, LIQT

LiqTech

$5.58 /

-0.15 (-2.62%)

, TNP

TEN, Ltd.

$2.12 /

-0.095 (-4.29%)

Investor Growth Virtual…

Investor Growth Virtual Conference will be held on June 24-25 at 9 am. Webcast Link

ShowHide Related Items >><<
TNP TEN, Ltd.
$2.12 /

-0.095 (-4.29%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.25 /

+ (+0.00%)

MOGO Mogo
$0.99 /

+0.0046 (+0.46%)

MNKD MannKind
$2.13 /

-0.08 (-3.63%)

LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

INFU InfuSystem
$12.31 /

+0.56 (+4.77%)

ICCC Immucell
$4.53 /

+0.03 (+0.67%)

EAST Eastside Distilling
$1.49 /

+0.04 (+2.76%)

CDXC ChromaDex
$4.57 /

-0.02 (-0.44%)

AZZ AZZ Inc.
$34.19 /

+0.52 (+1.54%)

MOGO Mogo
$0.99 /

+0.0046 (+0.46%)

06/04/20 B. Riley FBR
Mogo price target lowered to $3 from $4 at B. Riley FBR
03/30/20 B. Riley FBR
Mogo Finance price target lowered to $4 from $7 at B. Riley FBR
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
08/16/19 BMO Capital
Mogo Finance downgraded to Market Perform from Outperform at BMO Capital
SANW S&W Seed
$2.25 /

+ (+0.00%)

MNKD MannKind
$2.13 /

-0.08 (-3.63%)

12/24/19
Fly Intel: Top five analyst actions
12/24/19 Oppenheimer
MannKind initiated with an Outperform at Oppenheimer
10/25/19
Fly Intel: Top five analyst initiations
10/24/19 Cantor Fitzgerald
Cantor Fitzgerald starts MannKind at Overweight as Afrezza uptake gains traction
CDXC ChromaDex
$4.57 /

-0.02 (-0.44%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

EAST Eastside Distilling
$1.49 /

+0.04 (+2.76%)

AZZ AZZ Inc.
$34.19 /

+0.52 (+1.54%)

ICCC Immucell
$4.53 /

+0.03 (+0.67%)

INFU InfuSystem
$12.31 /

+0.56 (+4.77%)

06/09/20 Lake Street
InfuSystem initiated with a Buy at Lake Street
LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

01/22/20 Lake Street
LiqTech analyst increases confidence in recovery, says Lake Street
12/17/19 Lake Street
LiqTech to recover from furnace throughput challenges, says Lake Street
11/14/19 Craig-Hallum
LiqTech post-earnings pullback a buying opportunity, says Craig-Hallum
09/06/19 Stephens
LiqTech can materially ramp revenue and profits in 2020, says Stephens
TNP TEN, Ltd.
$2.12 /

-0.095 (-4.29%)

06/18/20
Fly Intel: Top five analyst downgrades
06/18/20 Stifel
TEN, Ltd. downgraded to Hold from Buy at Stifel
TNP TEN, Ltd.
$2.12 /

-0.095 (-4.29%)

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

SANW S&W Seed
$2.25 /

+ (+0.00%)

MNKD MannKind
$2.13 /

-0.08 (-3.63%)

LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

EAST Eastside Distilling
$1.49 /

+0.04 (+2.76%)

CDXC ChromaDex
$4.57 /

-0.02 (-0.44%)

AZZ AZZ Inc.
$34.19 /

+0.52 (+1.54%)

LIQT LiqTech
$5.58 /

-0.15 (-2.62%)

Syndicate
ChromaDex files $125M mixed securities shelf  16:32
06/12/20
06/12
16:32
06/12/20
16:32
CDXC

ChromaDex

$4.20 /

+0.045 (+1.08%)

 
ShowHide Related Items >><<
CDXC ChromaDex
$4.20 /

+0.045 (+1.08%)

CDXC ChromaDex
$4.20 /

+0.045 (+1.08%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
CDXC ChromaDex
$4.20 /

+0.045 (+1.08%)

Syndicate
ChromaDex files to sell 1.23M shares of common stock for holders  16:33
05/21/20
05/21
16:33
05/21/20
16:33
CDXC

ChromaDex

$4.68 /

-0.08 (-1.68%)

 
ShowHide Related Items >><<
CDXC ChromaDex
$4.68 /

-0.08 (-1.68%)

CDXC ChromaDex
$4.68 /

-0.08 (-1.68%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
CDXC ChromaDex
$4.68 /

-0.08 (-1.68%)

Earnings
ChromaDex says COVID-19 impact on revenues difficult to predict » 16:02
05/11/20
05/11
16:02
05/11/20
16:02
CDXC

ChromaDex

$5.53 /

+0.065 (+1.19%)

"Looking forward,…

"Looking forward, the impact of COVID-19 on revenues is difficult to predict and the Company is managing expenses to mitigate the bottom-line impact," ChromaDex said. "The Company does not expect any supply chain disruption at this time and, based on trends-to-date, expects continued revenue growth this year. Based on the Company's current financial outlook, revenue growth will be driven by its U.S. ecommerce business, new international market launches with its partners and distributors, such as in the U.K. and Australia, new online platforms, including Persona, a Nestle Health Science company, and our new product launch, Tru Niagen(R) Beauty. The Company expects continued gross margin improvement driven by a higher mix of Tru Niagen(R) sales, product design changes implemented in late 2019, and additional supply chain cost savings initiatives in 2020. The Company expects lower selling, marketing and advertising as well as general and administrative expenses as a percentage of net sales driven by strong growth from returning customers and scale on our fixed overhead costs driven by organizational realignment initiatives, as well as new systems and processes."

ShowHide Related Items >><<
CDXC ChromaDex
$5.53 /

+0.065 (+1.19%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer
Earnings
ChromaDex reports Q1 EPS (10c), consensus (11c) » 16:02
05/11/20
05/11
16:02
05/11/20
16:02
CDXC

ChromaDex

$5.53 /

+0.065 (+1.19%)

Reports Q1 revenue…

Reports Q1 revenue $14.3M, consensus $13.76M. "We had a strong first quarter with total net sales of $14.3 million and further global expansion," says ChromaDex CEO Rob Fried. "We made swift, targeted adjustments to the business, streamlining costs, updating marketing messages, and prioritizing scientific research focused on viral stress on immune response at the cellular level."

ShowHide Related Items >><<
CDXC ChromaDex
$5.53 /

+0.065 (+1.19%)

10/16/19
Fly Intel: Top five analyst initiations
10/16/19
Oppenheimer bullish on ChromaDex, initiates with an Outperform
10/15/19 Oppenheimer
ChromaDex initiated with an Outperform at Oppenheimer

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.